Decline in pediatric respiratory syncytial virus hospitalizations following nirsevimab implementation: A multicenter, three-season observational study
Objectives: To describe the demographic characteristics and clinical outcomes of hospitalized children with RSV in Catalonia during the first two seasons after the implementation of nirsevimab compared to the preceding season. Methods: This observational study included patients < 18 years hospita...
| Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2025 |
| Country: | España |
| Institution: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repository: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p6745 |
| Online Access: | https://i3pt.portalinvestigacion.com/publicaciones/6745 https://www.scopus.com/inward/record.uri?eid=2-s2.0-105022446787&doi=10.1016%2Fj.ijid.2025.108170&partnerID=40&md5=bb20a27e3fc71abe0711f7bc323f352b |
| Access Level: | Open access |
| Keyword: | Bronchiolitis Nirsevimab Respiratory syncytial virus Human Child Hospitalized |
| Summary: | Objectives: To describe the demographic characteristics and clinical outcomes of hospitalized children with RSV in Catalonia during the first two seasons after the implementation of nirsevimab compared to the preceding season. Methods: This observational study included patients < 18 years hospitalized across 12 Catalan hospitals during three RSV seasons: 2022-2023, 2023-2024, and 2024-2025. We collected demographic, clinical and microbiological data on patients with a laboratory-confirmed RSV-positive respiratory sample. Results: RSV-associated hospitalizations among < 6-month-olds declined by 66.7% and 77.6% in the 20232024 and 2024-2025 seasons, respectively, compared to the prenirsevimab season. This resulted in overall reductions of 40.8% and 28.4% across all age groups and an increase in patient median age (16.6 and 11.8 vs 4.8 months, P < 0.001). PICU admissions for under 6-month-olds decreased by 69.8% and 75.5%, with Median hospital length of stay and respiratory support duration both decreased by one day between 2022-2023 and 2024-2025. The proportion of patients with preexisting conditions such as asthma in Conclusions: After implementing nirsevimab, there was a significant decrease in pediatric RSV-associated hospitalizations and PICU admissions, especially among under 6-month-olds. The increase in patient median age and preexisting conditions highlight the need for new preventive strategies for these at-risk (c) 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) |
|---|